Allarity Therapeutics announced that multiple patients in its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer have maintained treatment for over 30 weeks. The dual PARP/Tankyrase inhibitor has demonstrated clear clinical benefits, including significant tumor shrinkage and long-term disease stability in heavily pre-treated patients with limited life expectancy.The trial utilizes Allarity's DRP companion diagnostic to select patients with higher likelihood of treatment benefit. The current protocol administers stenoparib twice daily (200mg morning, 400mg evening), modified from the previous once-daily 600mg dose. Notably, the drug shows a favorable safety profile compared to first-generation PARP inhibitors and chemotherapy alternatives.Based on these promising results, Allarity has halted patient enrollment to focus on developing a follow-on trial aimed at accelerating regulatory approval. The company plans to present the significant clinical data at an upcoming scientific conference. The PARP inhibitor market is projected to reach $22 billion by 2028, with increasing focus on developing treatments with improved tolerability and safety profiles.

Allarity Therapeutics announced that multiple patients in its Phase 2 clinical trial of stenoparib for advanced recurrent ovarian cancer have maintained treatment for over 30 weeks. The dual PARP/Tankyrase inhibitor has demonstrated clear clinical benefits, including significant tumor shrinkage and long-term disease stability in heavily pre-treated patients with limited life expectancy.The trial utilizes Allarity's DRP companion diagnostic to select patients with higher likelihood of treatment benefit. The current protocol administers stenoparib twice daily (200mg morning, 400mg evening), modified from the previous once-daily 600mg dose. Notably, the drug shows a favorable safety profile compared to first-generation PARP inhibitors and chemotherapy alternatives.Based on these promising results, Allarity has halted patient enrollment to focus on developing a follow-on trial aimed at accelerating regulatory approval. The company plans to present the significant clinical data at an upcoming scientific conference. The PARP inhibitor market is projected to reach $22 billion by 2028, with increasing focus on developing treatments with improved tolerability and safety profiles.